Vinpocetine Acre ®

General characteristics. Structure:

Active ingredient: 0,005 g of a Vinpocetine.

Excipients: sugar milk, aerosil, potato starch, magnesium stearate.

The Vinpocetine selectively improves blood supply of a brain and portability of cerebral ischemia.

Pharmacological properties:

Pharmacodynamics. The mechanism of selective improvement by a Vinpocetine of hemodynamic indicators of a brain blood-groove is caused by direct spasmolytic myotropic action on brain vessels. At the same time drug does not influence such parameters of blood circulation as pulse rate, the general peripheric vascular resistance, etc. Causes small decrease in system arterial pressure.

Strengthens regional blood circulation in an ischemic zone of a brain, without causing a phenomenon of "burglarizing". The Vinpocetine improves microblood circulation in brain vessels, slows down aggregation of thrombocytes, reduces the increased viscosity of blood, increases resistance of erythrocytes to deformation. Improves portability hypoxia brain cells, strengthens aerobic process of utilization of glucose. Has ability to brake activity of phosphodiesterase that leads to accumulation in cells of a brain of cyclic AMF. Increases the maintenance of catecholamines in a brain.

Pharmacokinetics. At intake bioavailability of a Vinpocetine makes 57%. The maximum concentration in blood is reached in 1 hour. Elimination half-life about 5 hours.

Indications to use:

Mental and neurologic symptoms of frustration of cerebral circulation of various origin (after the had stroke, a craniocereberal injury), such as memory disturbance, motive frustration, dizzinesses, headache.

Dynamic insufficiency of cerebral circulation of vascular character, ischemic damages of a brain, atherosclerosis of vessels of a brain.

In ophthalmologic practice: at vascular diseases of a retina and/or a choroid of an eye, at the degenerative changes of a macula lutea caused by atherosclerosis or a vasomotor spasm, secondary glaucoma.

In otorhinolaryngology: at senile relative deafness, Minyer's disease, at deterioration in hearing vascular or toxic (including medicamentous) genesis, at dizziness of a labyrinth origin.

Route of administration and doses:

Drug is accepted inside on 0,005-0,01 g (1-2 tablets) by 3 times a day. Apply it is long. Improvement is observed usually in 1-2 weeks. Course of treatment not less than 2 months.

Features of use:

It is necessary to be careful during the work with mechanisms.

Side effects:

The insignificant lowering of arterial pressure, is rare - tachycardia, premature ventricular contraction. Delay of intra ventricular conductivity.

Interaction with other medicines:

There are no data on any clinically significant medicinal interactions of a Vinpocetine.

Contraindications:

Pregnancy, lactation, the increased individual sensitivity.

With care appoint to patients with severe forms of cardiac arrhythmias and heavy coronary heart disease.

Overdose:

So far overdose cases were not registered. At accidental intoxication the general methods of removal of medicine from an organism and a symptomatic treatment are recommended. Special attention should be paid to function of cardiovascular system and respiratory system.

Storage conditions:

List B. In the dry, protected from light place, at a temperature not above 25 °C. To store in the place, unavailable to children. Not to use after the period of validity specified on packaging. A period of validity - 3 years.

Issue conditions:

According to the recipe

Packaging:

Tablets on 0,005 g. On 10 or 50 tablets in a blister strip packaging. 5 blister strip packagings on 10 tablets or 1 planimetric cell упаковкупо 50 tablets in a pack.